Genmab Cash from 2010 to 2024

GMAB Stock  USD 21.70  0.14  0.64%   
Genmab AS's Cash is increasing over the years with slightly volatile fluctuation. Overall, Cash is expected to go to about 15.6 B this year. Cash is the total amount of money in the form of currency that Genmab AS has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2009-12-31
Previous Quarter
4.3 B
Current Value
6.3 B
Quarterly Volatility
4.5 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Genmab AS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab AS's main balance sheet or income statement drivers, such as Depreciation And Amortization of 252 M, Interest Expense of 16.6 M or Selling General Administrative of 3.5 B, as well as many indicators such as Price To Sales Ratio of 8.12, Dividend Yield of 0.0 or PTB Ratio of 5.55. Genmab financial statements analysis is a perfect complement when working with Genmab AS Valuation or Volatility modules.
  
Check out the analysis of Genmab AS Correlation against competitors.
For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

Latest Genmab AS's Cash Growth Pattern

Below is the plot of the Cash of Genmab AS over the last few years. Cash refers to the most liquid asset of Genmab AS, which is listed under current asset account on Genmab AS balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Genmab AS customers. The amounts must be unrestricted with restricted cash listed in a different Genmab AS account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Genmab AS's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genmab AS's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Genmab Cash Regression Statistics

Arithmetic Mean4,274,211,200
Geometric Mean1,136,500,142
Coefficient Of Variation130.76
Mean Deviation4,695,505,867
Median873,986,000
Standard Deviation5,588,821,832
Sample Variance31234929.5T
Range15.5B
R-Value0.88
Mean Square Error7764800.1T
R-Squared0.77
Significance0.000018
Slope1,096,009,989
Total Sum of Squares437289012.5T

Genmab Cash History

202415.6 B
202314.9 B
20229.9 B
2021B
20207.3 B
20193.6 B
2018532.9 M

Other Fundumenentals of Genmab AS

Genmab AS Cash component correlations

About Genmab AS Financial Statements

Genmab AS stakeholders use historical fundamental indicators, such as Genmab AS's Cash, to determine how well the company is positioned to perform in the future. Although Genmab AS investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genmab AS's assets and liabilities are reflected in the revenues and expenses on Genmab AS's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genmab AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash14.9 B15.6 B
Cash And Short Term Investments28.1 B29.5 B
Change In CashB5.2 B
Free Cash FlowB7.4 B
Begin Period Cash Flow9.9 B10.4 B
Other Cashflows From Financing Activities49 M46.5 M
Other Non Cash Items-622 M-590.9 M
Total Cash From Operating Activities7.4 B7.7 B
Total Cash From Financing Activities-606 M-575.7 M
End Period Cash Flow14.9 B15.6 B
Total Cashflows From Investing Activities-2.5 B-2.4 B
Other Cashflows From Investing Activities-1.7 B-1.6 B
Free Cash Flow Yield 0.05  0.05 
Operating Cash Flow Per Share 113.00  118.65 
Free Cash Flow Per Share 107.24  112.60 
Cash Per Share 430.79  452.33 
Capex To Operating Cash Flow 0.05  0.06 
EV To Operating Cash Flow 17.16  28.12 
EV To Free Cash Flow 18.08  17.18 
Price To Operating Cash Flows Ratio 19.07  28.58 
Price To Free Cash Flows Ratio 20.09  19.09 
Cash Ratio 5.99  6.28 
Cash Conversion Cycle-4.1 K-3.9 K
Operating Cash Flow Sales Ratio 0.45  0.47 
Free Cash Flow Operating Cash Flow Ratio 0.95  1.02 
Cash Flow Coverage Ratios 2.08  1.38 
Price Cash Flow Ratio 19.07  28.58 
Cash Flow To Debt Ratio 2.08  1.38 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out the analysis of Genmab AS Correlation against competitors.
For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.38)
Earnings Share
1.02
Revenue Per Share
30.6997
Quarterly Revenue Growth
0.176
Return On Assets
0.1095
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.